January 30, 2013 - (Pluristem) - "Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has taken possession of and is moving into its new state-of-the-art GMP facility. The facility allows for the production of mass quantities of PLacental eXpanded (PLX) cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology." Read Full Press Release
